Clinical Trial Detail

NCT ID NCT03498612
Title Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Washington
Indications

follicular lymphoma

lymphoplasmacytic lymphoma

marginal zone B-cell lymphoma

CLL/SLL

Waldenstroem's macroglobulinemia

Therapies

Pembrolizumab

Age Groups: adult senior

No variant requirements are available.